MULTIPLE MYELOMA

Elizabeth "Betsy" O’Donnell, MD, discusses the importance of carrying out different strategies when treating patients with multiple myeloma who are older and frail.

Results from 2 studies shows ciltacabtagene autoleucel to prolong progression-free survival and induce response in patients with relapsed or refractory multiple myeloma.

At the 11th Annual Meeting of the Society of Hematologic Oncology, a debate was held between Angela Dispenzieri, MD, and Sagar Lonial, MD, FACP, about treatment decisions for smoldering multiple myeloma.

In an interview with Targeted Oncology, Binod Dhakal, MD, discussed results from the phase 3 CARTITUDE-4 study of cilta-cel in patients with lenalidomide-refractory multiple myeloma.

In a live, virtual event, Chakra Chaulagain, MD, discussed the results of the GRIFFIN trial in patients with newly diagnosed multiple myeloma when adding daratumumab to their traditional triplet therapy.

In the first article of a 2-part series, Ajay Nooka, MD, MPH, discussed both the initial and follow-up results of the MajesTEC-1 trial that showed the potency of teclistamab in patients with relapsed/refractory multiple myeloma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Joshua Richter, MD, and participants discussed second-line therapy options for a patient with high-risk relapsed multiple myeloma after frontline lenalidomide, bortezomib, and dexamethasone followed by autologous stem cell transplant.

FDA notices NXC-201 for its potential offer a novel mechanism to treat patients with multiple myeloma.

During an Oncology Town Hall™ virtual meeting, 4 investigators in multiple myeloma addressed emerging therapies, optimal sequencing, the role of minimal residual disease to inform therapy, and the possibility of storing T cells for use in later CAR T-cell therapy.

Prior suspicions about a patient death in iMMagine-1 had been cleared up and the trial will continue with the permission of the FDA.

In an interview with Targeted Oncology, Hans C. Lee, MD, discussed the safety and efficacy results of the phase 2 LINKER-MM1 study.

Findings from 2 cohorts of the phase 3 MagnetisMM-3 trial led to the FDA approval of elranatamab-bcmm for relapsed or refractory multiple myeloma treatment.

Data from the phase 2 MonumenTAL-1 study support the accelerated approval of talquetamab in patients with relapsed/refractory who have received at least 4 prior lines of therapy.

During a Targeted Oncology™ Case-Based Roundtable™ event, Ariel F. Grajales-Cruz, MD, and other physicians discussed how to manage toxicities and counsel patients when using selinexor for relapsed/refractory multiple myeloma.

Results from the CARTITUDE-2 trial of cilta-cel for multiple myeloma support the use of chimeric antigen receptor T-cell therapy earlier in therapy than what is currently approved.

During a Targeted Oncology™ Case-Based Roundtable™ event, Ariel F. Grajales-Cruz, MD, discussed the case of a patient who relapsed after receiving first- and second-line regimens for multiple myeloma. This is the first of 2 articles based on this event.

During a Targeted Oncology Case-Based Roundtable event, Cristina Gasparetto, MD, discussed the case of a patient with stage I multiple myeloma and highlighted outcomes of the phase 3 BOSTON trial.

In a comparison of 2 live events from the Targeted Oncology Case-Based Roundtable series, we look at how adding daratumumab to therapy for patients with newly diagnosed disease who cannot receive a transplant has shifted the approach to treatment.

Leo Shunyakov, MD, discussed long-term treatments and trials for patients with newly diagnosed multiple myeloma.

In an interview with Targeted Oncology, Yael C. Cohen, MD, senior physician in the Department of Hematology at Tel-Aviv Sourasky Medical Center, discussed the results from RedirecTT-1 she presented at ASCO 2023.

During a Targeted Oncology™ Case-Based Roundtable™ event, Carol Ann Huff, MD, and other physicians discussed how they expect to use bispecific agents and CAR T-cell therapy in patients with relapsed/refractory multiple myeloma as the field advances.

During a Targeted Oncology™ Case-Based Roundtable™ event, Ariel F. Grajales-Cruz, MD, discussed second-line therapy combinations for a patient with early-relapse multiple myeloma after complete remission with bortezomib, lenalidomide, and dexamethasone.

During a Targeted Oncology™ Case-Based Roundtable™ event, Chakra P. Chaulagain, MD, and participants discussed how they would treat a 54-year-old woman diagnosed with transplant-eligible R-ISS stage 2/R2-ISS stage 3 IgG-κ myeloma.

In the second article of a 2-part series, Alfred Garfall, MD, discussed how to best treat patients with multiple myeloma after they undergo transplant and whether continuing quadruplet therapy can provide a benefit before maintenance therapy.

In an interview, Emma Searle, MBChB, PhD, MA, MRCP, FRCPath, discussed results from cohort E of the MajesTEC-2 study of teclistamab in relapsed/refractory multiple myeloma.

In separate, live virtual events, Jonathan L. Kaufman, MD, and Morie A. Gertz, MD, MACP, discussed concerns about using chimeric antigen receptor T-cell therapy for a patient with relapsed/refractory multiple myeloma who is experiencing rapid disease progression.

In an interview with Targeted Oncology, Ajay K. Nooka, MD, MPH, FACP, discussed data from a pooled analysis of studies from the MagnetisMM program evaluating erlanatamab in relapsed/refractory multiple myeloma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Binod Dhakal, MD, MS, and participants discussed which treatment should come next for a patient with relapsed multiple myeloma depending on the patient's ability to travel for care.

During a Targeted Oncology™ Case-Based Roundtable™ event, Carol Ann Huff, MD, discussed the choice of therapy for a patient with relapsed/refractory multiple myeloma. This is is the first of 2 articles based on this event.

Although dosing will continue in iMMagine-1 for patients who responded well to CART-ddBCMA, recruitment has been halted due to to a safety concern.